A recent FCF Life Sciences analysis showed a significant decline in funding volumes for European life sciences markets in the first half of 2022 compared to 2021. This trend is now confirmed for the US life sciences markets as well. It affects all relevant subsectors, in particular Biotech and HealthTech.
The total financing volumes declined by almost a quarter from USD 45.1bn to USD 34.9bn. The HealthTech subsector has been especially affected with a reduction in funding by more than -35 percent.
Interestingly, only Series B companies were able to attract more funding. The surplus is partly attributable to two deals in the MedTech sector: Noah Medical (USD 150m) and Biolinq (USD 116m). If excluded, the funding situation for Series B companies would also turn negative in H1/2022, resulting in a decline in funding for companies across all stages.
About FCF Life Sciences
FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.
Learn more about FCF Life Sciences, click here.
We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.
To hear from us on the latest insights, please sign up here: